Background: Oral contraceptive pills (OCPs) are currently used by approximately 16% of all women aged 15 to 44 in the United States and have been used by 80% of all sexually active women at some point in their lives. However, no guidelines exist for discontinuation of OCP therapy before or after elective cosmetic surgery. Objectives: The aim of this study is to establish current practice trends regarding perioperative OCP management in aesthetic surgery. Methods: An eight-item online survey was distributed to members of the American Society of Plastic Surgeons (ASPS). Survey results were analyzed to determine if surgeons' practice setting, years of experience, annual cosmetic volume, or types of cosmetic procedures performed affected their perioperative management of OCPs. Results: A total of 220 questionnaires were collected (11.9% response rate). Only 31.8% of surgeons reported any discontinuation of OCPs pre-or postoperatively. Among physicians, 7.3% reported only preoperative discontinuation, 24.5% reported OCP discontinuation both pre-and postoperatively, and 0.0% of physicians reported discontinuation of OCPs only postoperatively. There was no statistically significant difference between the percentage of surgeons in academic practice who discontinue OCPs perioperatively (P = 0.335). There was no statistical significance towards overall years in practice (P = 0.152). There were no significant differences between the three groups in the number of cosmetic procedures performed annually or percentage breakdown of procedures performed. Conclusions: Despite OCP therapy being a known risk factor for venous thromboembolic events, a majority of surgeons performing cosmetic surgery do not routinely recommend perioperative cessation. Editorial Decision date: November 2, 2017; online publish-ahead-of-print December 18, 2017.
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Venous thromboembolic events (VTEs) are a rare but increasingly well-recognized complication after aesthetic surgery, with 116 (0.09%) patients out of total of 129,007 patients over a 6-year period developing a VTE. 1 Subsequently, there has been a recent emphasis on interventions to decrease the likelihood of this potentially catastrophic event. In aesthetic surgery, the VTE risk increases with combined procedures and with those performed on particular areas of the body, most notably the trunk and extremities. In terms of patient demographics, advanced age and increased body mass index (BMI) are also associated with a higher rate of VTE following aesthetic plastic surgery. 1 Since many of these factors associated with increased VTE incidence are inherent to the patient and/or procedure, it is important for the surgeon to carefully consider any modifiable risk factors for VTE prior to surgery.
Oral contraceptive pills (OCPs) are currently used by ~16% of all women aged 15 to 44 and have been used by 80% of all sexually active women at some point in their lives. This demographic represents many of the patients presenting for cosmetic surgery. 2 OCP use is an established risk factor for VTE and is in included in the Caprini Risk Assessment Model, contributing an additional point to the overall Caprini score. 3, 4 However, no consensus guidelines exist for discontinuation of OCP therapy before or after elective cosmetic surgery. The aim of this study is to establish current practices regarding perioperative OCP management in aesthetic surgery.
METHODS
An 8-question survey pertaining to management of oral contraceptive pills in the aesthetic plastic surgery patient was created (Appendix A, available online as Supplementary Material at www.aestheticsurgeryjournal. com). The questionnaire was sent to 1844 contacts on the American Society of Plastic Surgery (ASPS) mailing list which consisted of functioning email addresses that could be located on the ASPS member website as of April 2015. This survey was designed by our research team and was not pretested or validated before mailing out. The study was exempt from Institutional Review Board approval in accordance with Federal regulations (45 CFR 46.101(b)).
Distribution and collection of the questionnaire was carried out utilizing SurveyMonkey (http://www.surveymonkey. com). The survey was sent in November of 2016 and two reminders were sent to those who were nonresponsive in twoweek increments over the following 6-week period and subsequently the survey was closed at the end of December 2016.
All analyses were performed using IBM SPSS version 24.0 (IBM Corp., Armonk, NY). Survey results were analyzed to determine if surgeon practice setting, years of experience, annual aesthetic case volume, or types of procedures performed affected their perioperative management of OCPs. Pearson chi-square was performed to evaluate trends among categorical variables. Mann-Whitney U test was used to test for differences in means of continuous variables between groups. Logistic regression was used to determine predictors of OCP discontinuation. A P value of < 0.05 was considered statistically significant.
RESULTS

Overall Results
A total of 220 completed surveys were collected, yielding a response rate of 11.9%. Only 31.8% of surgeons reported any discontinuation of OCPs preoperatively or postoperatively. Among physicians, 7.3% reported only preoperative discontinuation, 24.5% reported OCP discontinuation both preoperatively and postoperatively, and 0.0% of physicians reported discontinuation of OCPs only postoperatively. Mean time of preoperative discontinuation (weeks) is 2.86 ± 1.32. Mean time of preoperative discontinuation (weeks) is 2.26 ± 1.38. Overall results are shown in Table 1 .
Respondent Demographics
Mean number of years in practice for the survey respondents was 21.51 ± 9.28. Number of cosmetic procedures annually was 190.9 ± 157. Percentage breakdown of cosmetic procedures by type of procedure were 22.16%, 44.42%, 34.54% for face, breast, and body contouring procedures, respectively. Survey respondent demographics are shown in Table 1 .
Discontinuation Practices
There was no statistically significant difference between the percentage of surgeons in academic practice who discontinue OCPs perioperatively (P = 0.335). There was no statistical significance towards overall years in practice (P = 0.152). There were no significant differences between the three groups in number of cosmetic procedures performed annually, or percentage breakdown of procedures performed. Discontinuation practices are shown in Table 2 .
DISCUSSION
Our survey of ASPS members shows that only a minority of surgeons discontinue OCPs perioperatively in patients undergoing elective cosmetic surgery. These findings are noteworthy because of the established increase in VTE incidence associated with OCP therapy. In a systematic review on OCP use, De Bastos et al found that all combined oral contraceptive formulations investigated were associated with an increased risk of venous thrombosis. 5 In an American Society of Reproductive Medicine statement, it was discussed that there are no randomized trials large enough to compare thrombosis risk in patients on oral contraceptives containing different doses of estrogen but Grade B evidence suggests that high-dose combined oral contraception (>50 μg) is associated with higher risk of VTE than lower-dose formulations. 6 The physiological properties of estrogen may help clarify this link. Estrogen increases the biologic activity of procoagulant factors including factors 2, 7, 10, and 12 as well as fibrinogen, while decreasing the activity of coagulation inhibitors such as antithrombin 3 and protein S, creating an overall net prothrombotic effect. 7, 8 The reduction of estrogen dose in more modern OCP formulations that are already below 50 μg estrogen has unfortunately had a limited effect on reducing the risk of venous thrombosis. 8 It is important to also note that 2.6% of all contraceptive users use a vaginal ring for contraception. 2 Paresi Jr. et al reports on a series of two patients who both had a Nuvaring present preoperatively however, both patients denied being on the vaginal ring on the intake form as well as in the patient interview. 9 Postoperatively, both developed DVTs and subsequent pulmonary embolisms that were treated after being admitted to the hospital. It is important to note and discuss discontinuation of Nuvaring with women preoperatively as well. The American Society of Reproductive Medicine notes in their 2017 statement that there is insufficient evidence that the contraceptive patch or contraceptive vaginal ring has a different risk of VTE compared with combined oral contraceptives (Grade C). 6 This makes it important to screen about vaginal rings as well due to their nature as an estrogen containing product with a similar VTE profile to oral contraceptive pills.
Despite the known prothombotic effects of estrogen therapy, it appears that that many plastic surgeons in the United States are not intervening to eliminate this modifiable risk factor. In contrast, a survey of plastic surgeons in the United Kingdom found that 54% discontinued OCPs before surgery. 10 Another study of orthopaedic surgeons out of New Zealand found that 44% of surgeons surveyed would routinely advise discontinuing the OCPs perioperatively for major surgery. 11 However, our results show that only 31.8% of responding plastic surgeons routinely discontinue OCPs preoperatively in aesthetic surgery. Clearly, this is an area ripe for clinical investigation. In 2011, the ASPS Task Force released a VTE report which utilized a Caprini risk assessment model (RAM) to grade patients based on their VTE risk. The overall Caprini score can then be used to stratify patients into low, moderate, and high risk for VTE, with commensurate recommendations for each patient category (eg, systemic anticoagulation for high risk patients). In this model, OCP use is considered an identifiable risk factor for VTE, and adds 1 point to the overall RAM. 3 The lack of more widespread perioperative discontinuation of OCPs in the aesthetic surgery patient may be due to several factors. Patients undergoing elective aesthetic surgery tend to be healthier and younger (and thus have overall lower Caprini RAM scores) than other surgical patients. This means that most patients will have Caprini scores sufficiently low such that the additional point added by OCP use may not elevate the patient's stratification into a higher risk category. However, the Caprini model should be viewed as a global assessment of a patient's VTE risk, not just as a means of classifying patients into relative risk categories. Therefore, any modifiable factors to reduce overall VTE risk should be exploited when possible as an increasing 2005 Caprini score carries a logarithmic, not linear, increase in VTE risk. 4 This is of particular importance in the elective aesthetic patient, in whom the margins for error and tolerance of complications are very small. Another complicating factor in the perioperative management of OCPs may be related to the nature of the medication. The discussion of sexual activity and pregnancy risk can be a sensitive topic that surgeons might rather avoid. Likewise, a patient may be hesitant to accept the ramifications of temporarily stopping her OCP therapy. Whenever possible, aesthetic surgeons may choose to delay surgery to optimize VTE risk and thus overall patient safety in patients who have modifiable risk factors such as smoking history or modifiable weight loss. In the same line of thought, why not delay surgery as well in patients on current OCP therapy? Thus, we feel that possibly a delay in surgery in order to stop OCP therapy may be advisable in specific patient populations to improve overall patient safety. Also of interest is the average duration of preoperative and postoperative OCP discontinuation among plastic surgeons in this survey (2.86 and 2.26 weeks respectively). The British National Formulary recommends that combined oral contraceptives should be discontinued at least 4 weeks before surgery. 10 OCP manufacturers also recommend discontinuation 4 weeks before elective surgery and 2 weeks postoperatively. 11 A survey of UK plastic surgeons illustrated that the most common duration of OCP discontinuation was even longer, ranging from 5 to 6 weeks. 10 This demonstrates a regional variation in perioperative OCP management between plastic surgeons in the United States and the United Kingdom. The difference may result from the lack of national consensus guidelines on this issue in the United States.
A previous survey of plastic surgeons showed that a DVT had occurred in over one third of plastic surgeons' practices with 7% of surgeons reporting a patient death from pulmonary embolism after body contouring surgery. 12 Likewise, 4% of surgeons reported a death secondary to pulmonary embolism (PE) following autologous breast reconstruction. 13 However, it is unclear how these statistics translate for the aesthetic surgery patient, who tends to be healthier and undergoing a procedure of shorter duration. 14 In fact, many plastic surgeons seem to ignore the risk of VTE in the aesthetic population and do not employ any forms of prophylaxis. Among those surgeons performing face lifts, 16.4% reported not using any deep vein thrombosis prophylaxis; for those surgeons performing liposuction, 21.3% did not use any deep vein thrombosis prophylaxis and 8.7% of surgeons performing a combined abdominoplasty-liposuction procedure did not use any deep vein thrombosis prophylaxis. 14 However, even after a relatively low risk procedure like rhytidectomy, the estimated rates of DVT and PE are 0.35% and 0.14% respectively. 15 Another recent study found that in a cohort of rhinoplasty patients there was a 0.0% DVT rate and found that most of these patients fell into the "low risk" Caprini stratification. 16 However, given the significant morbidity and/or mortality that can result from VTE, appropriate risk stratification should always be considered, even in those patients at very low risk. It has been previously shown that VTE risk peaks at three weeks after surgery in middle aged women and remains substantially elevated for up to 12 weeks. This makes it even more imperative as high-risk aesthetic plastic surgery patients would benefit from delay of the surgical procedure in order to minimize the Caprini risk factors that would result in a lowered VTE risk.
In order to maximize response rate, the survey utilized in this study was designed to be concise. However, this brevity resulted in the main limitation of this study: it did not elucidate the surgeon's rationale for perioperative OCP management. We also did not ask respondents specifically about different OCP formulations, as there has been a link to the prothrombotic effect size relative to estrogen used. 17 This may have helped to further clarify respondent reasoning. On this note, also the entire cohort of ASPS members was not surveyed and may not represent the entire cohort of aesthetic plastic surgeons. Another limitation of our current recommendation of OCP cessation is the occurrence of pregnancy and must be explained to patients preoperatively. If a patient were to discontinue her OCPs and become pregnant in the preoperative period, she would actually have a higher risk of VTE then if she were on her original OCP formulation, and subsequently this again is important to address with patients in the preoperative period. 18 Nonetheless, the results of this survey demonstrate significant variability in perioperative management of OCPs in the aesthetic surgery population, indicating a need for further higher-level research.
CONCLUSIONS
Despite OCP therapy being a known risk factor for VTE, a majority of surgeons performing aesthetic surgery do not routinely recommend perioperative cessation. It remains our responsibility as plastic surgeons to minimize perioperative complications, and especially so in the aesthetic surgery patient, and thus future studies are needed to standardize guidelines regarding OCP discontinuation in aesthetic surgery and delineate the patient population most likely to benefit from perioperative discontinuation.
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